



“Cancure’s mission is to develop breakthrough drugs that push the limits of anti-cancer response rates, and hasten the evolution of cancer treatments into cancer cures.”
Cancure is a biopharmaceutical company founded in 2012, with the aim of investing in therapies capable of countering several major diseases afflicting society today.
Cancure has developed a suite of breakthrough oncology therapies, which employ innovative methods to enhance the body’s anti-cancer immune response, or kill cancer cells by exploiting novel targets within them. These revolutionary therapies are ideally positioned in the emerging fields of immuno-oncology, combination therapies and mitochondrial biology.
Cancure is developing these therapies into marketable drugs that push the limits of anti-cancer response rates and hasten the evolution of cancer treatments into cancer cures.
News
- NousCom receives $49M to trial off-the-shelf cancer vaccine November 9, 2017
- AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans November 1, 2017
- Incyte pays MacroGenics $150M for PD-1 inhibitor October 26, 2017
- Gilead buys CAR-T developer Kite Pharma for $12B August 29, 2017
Contact
Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218